Linda van der Tol1, Camiel Verhamme2, Ivo N van Schaik2, Anneke J van der Kooi2, Carla E M Hollak1, Marieke Biegstraaten3,4. 1. Department of Endocrinology and Metabolism, Amsterdam lysosome center 'Sphinx', Amsterdam, The Netherlands. 2. Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Endocrinology and Metabolism, Amsterdam lysosome center 'Sphinx', Amsterdam, The Netherlands. M.Biegstraaten@amc.uva.nl. 4. Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Room F5-166, Meibergdreef 9, 1105, Amsterdam, The Netherlands. M.Biegstraaten@amc.uva.nl.
Abstract
BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by an α-galactosidase A enzyme deficiency due to pathogenic variants in the α-galactosidase A gene (GLA). An increasing number of individuals with a GLA variant, but without characteristic FD features, are identified. A definite diagnosis of FD has important consequences for treatment and counselling. OBJECTIVES: We assessed the diagnostic value of quantitative sensory testing (QST) and intraepidermal nerve fibre density (IENFD) for patients with an uncertain FD diagnosis. METHODS: All patients with a GLA variant who initially presented at the Academic Medical Center with an uncertain FD diagnosis were included. A biopsy of an affected organ in a patient or family member showing FD characteristic storage is used as a reference standard for a diagnosis of FD. All patients underwent a comprehensive QST protocol and IENFD assessment which was compared to age and gender-matched healthy controls. Sensitivity and specificity were calculated for a combination of ≥1 abnormal QST modality and an abnormal IENFD. RESULTS: Twenty-six patients participated (nonclassical FD n = 18, 9 males; no FD n = 5, 3 males; uncertain n = 3, 1 male). Of the patients classified as nonclassical FD, 28% had ≥1 abnormal QST modalities, and 83% had an abnormal IENFD. From the patients without FD, 20% had ≥1 abnormal QST modality, and IENFD was abnormal in 25% (1 not available). Sensitivity was 28% and specificity 80%. CONCLUSIONS: In our study cohort, QST and IENFD could not reliably distinguish patients with FD from those without FD.
BACKGROUND:Fabry disease (FD) is an X-linked lysosomal storage disorder caused by an α-galactosidase A enzyme deficiency due to pathogenic variants in the α-galactosidase A gene (GLA). An increasing number of individuals with a GLA variant, but without characteristic FD features, are identified. A definite diagnosis of FD has important consequences for treatment and counselling. OBJECTIVES: We assessed the diagnostic value of quantitative sensory testing (QST) and intraepidermal nerve fibre density (IENFD) for patients with an uncertain FD diagnosis. METHODS: All patients with a GLA variant who initially presented at the Academic Medical Center with an uncertain FD diagnosis were included. A biopsy of an affected organ in a patient or family member showing FD characteristic storage is used as a reference standard for a diagnosis of FD. All patients underwent a comprehensive QST protocol and IENFD assessment which was compared to age and gender-matched healthy controls. Sensitivity and specificity were calculated for a combination of ≥1 abnormal QST modality and an abnormal IENFD. RESULTS: Twenty-six patients participated (nonclassical FD n = 18, 9 males; no FD n = 5, 3 males; uncertain n = 3, 1 male). Of the patients classified as nonclassical FD, 28% had ≥1 abnormal QST modalities, and 83% had an abnormal IENFD. From the patients without FD, 20% had ≥1 abnormal QST modality, and IENFD was abnormal in 25% (1 not available). Sensitivity was 28% and specificity 80%. CONCLUSIONS: In our study cohort, QST and IENFD could not reliably distinguish patients with FD from those without FD.
Authors: G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé Journal: Eur J Neurol Date: 2010-07 Impact factor: 6.089
Authors: Marieke Biegstraaten; Andreas Binder; Rainer Maag; Carla E M Hollak; Ralf Baron; Ivo N van Schaik Journal: Eur J Pain Date: 2011-02-22 Impact factor: 3.931
Authors: W Terryn; R Vanholder; D Hemelsoet; B P Leroy; W Van Biesen; G De Schoenmakere; B Wuyts; K Claes; J De Backer; G De Paepe; A Fogo; M Praet; B Poppe Journal: JIMD Rep Date: 2012-07-29
Authors: R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka Journal: Pain Date: 2006-05-11 Impact factor: 6.961
Authors: Satu M Laaksonen; Matias Röyttä; Satu K Jääskeläinen; Ilkka Kantola; Maila Penttinen; Björn Falck Journal: Clin Neurophysiol Date: 2008-04-01 Impact factor: 3.708
Authors: L van der Tol; B E Smid; B J H M Poorthuis; M Biegstraaten; R H Lekanne Deprez; G E Linthorst; C E M Hollak Journal: J Med Genet Date: 2013-08-06 Impact factor: 6.318
Authors: M Bakkers; I S J Merkies; G Lauria; G Devigili; P Penza; R Lombardi; M C E Hermans; S I van Nes; M De Baets; C G Faber Journal: Neurology Date: 2009-10-06 Impact factor: 9.910
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391